P-1648. Efficacy of Co-Ultramicronized Palmitoylethanolamide With Luteolin for Managing Post-COVID-19 Persistent Olfactory Dysfunction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Abstract
Abstract Background Persistent olfactory dysfunction (OD) after long COVID-19 is an emerging global health concern. However, evidence-based therapies for persistent OD post-COVID-19 remain limited. This meta-analysis aims to assess the effectiveness of co-ultramicronized palmitoylethanolamide with luteolin (um-PEA-LUT) combined with olfactory training (OT) for managing post-COVID-19 OD. Methods PubMed, Scopus, Web of Science, Embase, and Cochrane databases were systematically searched. Randomized clinical trials (RCTs) comparing um-PEA-LUT plus OT versus OT alone in treating post-COVID-19 OD were included. The primary outcome was the change in Sniffin’ Sticks test scores for Threshold, Discrimination, and Identification (TDI). Statistical analysis was performed using Review Manager software, and the results were presented as the mean difference (MD) with 95% confidence intervals (CI), employing a random-effect model. Results Four RCTs with a total of 367 patients were included in the meta-analysis. The combination of um-PEA-LUT and OT significantly improved the overall TDI score compared to OT alone (MD = 5.32, 95% CI [1.25, 9.39], p = 0.01). Significant heterogeneity in the TDI scores was identified but resolved through a sensitivity analysis, without affecting the significance of the results (MD = 6.86, 95% CI [2.82, 10.91], p = 0.0009). Conclusion The addition of um-PEA-LUT to OT resulted in significant improvements in the overall TDI score in patients with persistent…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 367 participants or records.
Read the paper
Related studies
- Luteolin rescues postmenopausal osteoporosis elicited by OVX through alleviating osteoblast pyroptosis via activating PI3K-AKT signaling
- Drugs Used in “Chemsex”/Sexualized Drug Behaviour—Overview of the Related Clinical Psychopharmacological Issues
- Luteolin Inhibits Dexamethasone‐Induced Osteoporosis by Autophagy Activation Through miR‐125b‐5p/SIRT3/AMPK/mTOR Axis, an In Vitro and In Vivo Study
- Cutting-edge insights into liver fibrosis: advanced therapeutic strategies and future perspectives using engineered mesenchymal stem cell-derived exosomes
- Can we predict and manage persistent storage and voiding LUTS following bladder outflow resistance reduction surgery in men? ICI‐RS 2023
- Chylomicron-mimicking supramolecular nano emulsion for oral luteolin delivery against hyperuricemia
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.